Capital World Investors Clovis Oncology, Inc. Transaction History

Capital World Investors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $13 Million - $37.9 Million	-3,443,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $6.61 Million - $25.8 Million	1,682,963 Added 95.62%	3,443,000 $13.5 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $15.7 Million - $31.5 Million	1,227,037 Added 230.21%	1,760,037 $26.2 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $3.5 Million - $5.89 Million	-119,000 Reduced 18.25%	533,000 $15.7 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $32.7 Million - $44.2 Million	652,000 New	652,000 $34.4 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.